Press Release: OncoResponse : OncoResponse Announces Preclinical Data Highlighting OR2805 Discovery from Elite Responder Platform and OR502 anti-LILRB2 Antibody at SITC 2022

- OR2805 increases T cell activation and proliferation, amplifies anti-PD1 activity, and demonstrates robust anti-tumor activity - - OR502 specifically binds and blocks LILRB2, relieves immunosuppression,...